The final, formatted version of the article will be published soon.
EDITORIAL article
Front. Cardiovasc. Med.
Sec. Atherosclerosis and Vascular Medicine
Volume 11 - 2024 |
doi: 10.3389/fcvm.2024.1516185
This article is part of the Research Topic Role of Colchicine in Atherosclerosis View all 5 articles
Editorial: Role of Colchicine in Atherosclerosis
Provisionally accepted- 1 Heart Research Institute, Sydney, Australia
- 2 Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
- 3 South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia
- 4 Harry Perkins Institute of Medical Research, Murdoch, Western Australia, Australia
Colchicine may enhance plaque integrity by promoting collagen deposition and increasing the cap-to-necrotic core ratio, while simultaneously attenuating pro-atherogenic lipid burden. It further inhibits the activation of the NLRP3 inflammasome, a key molecular driver of inflammatory cytokine production, leading to an overall reduction in local inflammatory responses. Other critical aspects of innate immunity are likewise impaired following colchicine administration, specifically neutrophil recruitment to the plaque site and downstream effector functions, including NET (Neutrophil Extracellular Trap)-osis and degranulation. Additional atheroprotective functions include the prevention of vascular smooth muscle cell transdifferentiation from contractile to detrimental synthetic phenotypes, and the modulation of cholesterol crystal formation and morphology; all cumulatively reducing plaque destabilization.In their review article 9 published in this special issue on colchicine in cardiovascular disease, Bulnes and co-workers elaborate on the converging evidence from both animal and clinical studies that show the suppressive effect of colchicine upon the NLRP3 inflammasome, a protein complex that, when activated in inflammatory cells, promotes the production of potent inflammatory, pro-atherosclerotic cytokines, namely interleukin (IL)-1β and IL-18. Cholesterol crystals, which form in the artery wall as the consequence of cholesterol accumulation in plaque, are one such triggering agent for NLRP3 activation.In their research paper, Abideen et al. 10 detail an inverse relationship between the dose of colchicine used and the formation and expansion of cholesterol crystals in vitro, potentially elucidating the drug's indirect effects on inhibiting NLRP3 activation. This is important as there is striking evidence that the accumulation of cholesterol crystal in atherosclerotic plaque can lead to acute plaque rupture 11, 12 . In vitro assays of rat and rabbit biological membranes viewed using scanning electron microscopy (SEM) showed that cholesterol crystals were able to distort and protrude through the tissue using their sharp geometric edges 11 . This was similarly noted in ex vivo findings from human arterial tissues and plaques, prepared using vacuum dehydration for SEM, detecting cholesterol crystals disrupting the plaque and penetrating the intimal surface 11,12 .Abideen et al. provide a novel mechanism by which colchicine may reduce the risk of acute plaque rupture, by showing that it can also slow the rate of cholesterol crystal formation and alter its morphology 10 . Post-drug treatment, SEM of both in vitro samples and ex vivo samples of human carotid atherosclerotic plaques showed evidence of morphological changes in cholesterol crystals relating to the loss of their sharp edges which, as mentioned, can directly perforate the plaque and trigger atherothrombosis. It remains to be seen if these findings can be replicated in vivo.One of the most recognised actions of colchicine on inflammation, is its inhibitory effect on neutrophil function. However, it is also well-documented to affect the properties of macrophages, endothelium and smooth muscle cells, and dampen the interaction between neutrophils and platelets, which may mitigate against plaque growth, improve plaque stability and reduce the risk of thrombotic occlusion 13,14 . These atheroprotective effects have been exhibited in a mouse model of unstable carotid plaques induced by tandem stenosis surgery, where colchicine was shown to decrease lesion size and necrotic core area, along with increasing collagen and the cap-to-necrotic ratio 13 . Interestingly, it has also been recently identified to modulate the transition of detrimental smooth muscle cell phenotypes 14 .Tubulin binding, and subsequent disruption of microtubulin formation, prevents the recruitment and invasion of neutrophils into plaques by disrupting their motility and expression of adhesion molecules. Colchicine further suppresses the formation of neutrophil extracellular traps (NETs): web-like structures released upon neutrophil activation that enhance platelet aggregations and potent cytokine release within the plaque microenvironment 13,15 . A 2021 study by Vaidya et al., showed that colchicine was able to restore cytoskeletal dynamics, and prevent NET formation, in neutrophils of acute coronary syndrome patients post-percutaneous coronary intervention 15 . Based on this evidence, Bulnes and colleagues suggest that early administration of colchicine may also modulate initial tissue-damaging responses to ischaemic and reperfusion injury in the setting of acute MI, by preventing detrimental recruitment and activation of innate immune cells.In another paper in this series, Mohammadnia et al. report on a post hoc analysis of the effect of colchicine in patients with diabetes from the LoDoCo2 trial 16 . They identified that colchicine resulted in similar reductions in the rate of MACE in people with stable coronary artery disease, irrespective of diabetes status. They also explored whether colchicine might influence the onset of new diabetes and provided weak evidence that it may be protective, which requires further investigation. Indeed, larger prospective trials designed to assess the effect of colchicine specifically in patients with diabetes or on the incidence of new onset diabetes have yet to be seen. Apart from monitoring changes in diabetic treatment and glycaemic control, these studies would need to account for other variables influencing inflammation such as body mass index and diet.It is recognised that even at low dose, colchicine can cause gastrointestinal symptoms including diarrhea and nausea, however these are typically mild and self-limiting. More importantly, physicians need to be aware that in patients with advanced renal disease or liver failure there is an increased potential for adverse drug interactions, most especially with clarithromycin, cyclosporin and some anti-fungal and anti-viral agents. Those issues aside, low-dose colchicine is safe, as it does not affect renal or liver function, and there have been no reports of drug-drug interactions with other cardiovascular medications, including all forms of statins even when used at high dose 17 . Thus, based upon updated cardiovascular guidelines throughout the world, low-dose colchicine should be considered in patients with high risk of future cardiovascular events based upon a history of MI, stroke or prior revascularisation, as well as those with high coronary calcium scores 18 .Clearly, we have entered a new and exciting era of cardiovascular management in which antiinflammatory therapy will contribute to the care of patients with ASCVD. Going forward, ongoing and future studies will help determine if there is also a role for newer anti-inflammatory agents with more pathway-targeted actions than colchicine, as these will be needed to treat patients with renal disease in whom colchicine is contraindicated and those who are intolerant to colchicine therapy.
Keywords: atheroscelorsis, Inflammation, Coronary artery diasease, IL1 Beta, Macropahge, Colchicine
Received: 24 Oct 2024; Accepted: 08 Nov 2024.
Copyright: © 2024 MISRA, Psaltis and Nidorf. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
ASHISH MISRA, Heart Research Institute, Sydney, Australia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.